Amgen Inc.

The provided transcript does not mention any current or future fundraising plans through debt or equity. Key relevant points include: - The company is focused on capital allocation amid intense industry competition. - They emphasize strong execution, portfolio growth, and R&D investment. - No explicit mention of raising funds through issuing debt or equity. - The CFO notes a commitment to growth, productivity, and financial discipline. - They are actively investing in biosimilars and innovative pipelines but do not indicate seeking external capital infusion. - Instead, the company highlights internal capital allocation and strategic investments for growth. In summary, there is no indication in the transcript of planned fundraising via debt or equity at this time.

- Amgen plans to increase R&D investment in 2021, focusing on promising mid-stage pipeline candidates and early research strategies such as human genetics and induced proximity platform technologies. - Continued allocation of capital to biosimilars is emphasized, with biosimilar franchises maintaining very competitive margins and Amgen leveraging strong execution capabilities. - Investments are also directed towards digitization and automation to enhance operational productivity. - Strategic investments include expanding digital capabilities and commercial field organization reshaping to improve efficiency and share of voice post-COVID. - Emphasis on capital discipline, balancing internal innovation with external partnerships and acquisitions, e.g., previous acquisition of New Evolution to build capabilities in protein degradation and induced proximity. - Commitment to ESG initiatives implies capital allocation toward sustainability goals, including achieving carbon neutrality by 2027 and reducing waste.

- Amgen expects continued revenue growth driven by volume increases in key products such as Prolia, Otezla, Repatha, EVENITY, and a growing innovative oncology portfolio. - International expansion plans, particularly for Otezla (Japan, Australia) and biosimilars across multiple markets, are anticipated to contribute to growth. - Launch preparations for new products like Sotorasib and Tezepelumab are expected to drive future sales. - Despite mid-single digit net price declines expected due to competition and pricing pressures, volume growth is the key revenue driver. - Growth from biosimilars remains a strong capital allocation focus, with leading US market shares in key biosimilars. - The mild to moderate psoriasis indication approval and global expansion for Otezla are seen as major growth opportunities. - Continued investments in digital capabilities aim to improve commercial model productivity post-COVID, supporting sustained market penetration. - Anticipated 2021 revenue guidance is $25.8 billion to $26.6 billion, reflecting these growth factors.

- Amgen expects 5% non-GAAP EPS growth year-over-year for Q4 2020 and 12% non-GAAP EPS growth for the full year 2020. - For 2021, non-GAAP earnings per share guidance is $12.12 to $13.17 per share. - Revenue guidance for 2021 is $25.8 billion to $26.6 billion. - Operating expenses expected to grow about 7% year-over-year in 2021 due to R&D investments and commercial/investment activities. - Operating margin targeted around 50% for 2021, supported by strong cost structure and revenue growth. - Mid-single digit declines in net selling prices are anticipated due to competition. - Amgen plans continued investments in innovation, new product launches, and digital commercial efforts. - Capital allocation includes investing in internal/external innovation and returning capital to shareholders via dividends and share repurchases.

The provided transcript does not specifically mention any details regarding the current or expected orderbook or pending orders for Amgen. The discussion mainly focuses on: - Product sales growth driven by volume increase (9% YoY growth, 15% volume growth). - Strong launch preparations and regulatory filings for key products like Sotorasib and Tezepelumab. - Expansion of global presence and commercial footprint (China, Japan, international markets). - Ongoing and anticipated regulatory submissions across multiple regions. - Commercial strategies including digital engagement and field force realignment. - No explicit figures or commentary on orderbook status or pending orders are disclosed in the available text.